Skip to main content
. 2018 Jun 8;9(44):27346–27362. doi: 10.18632/oncotarget.25213

Figure 2. Dasatinib inhibits the growth of NSCLC cells.

Figure 2

(A) Increasing concentrations of dasatinib inhibit autophosphorylation of SRC on Y416 in NSCLC (A549 and H460) and SCLC (H510) cells. Cell lysates were analysed by SDS-PAGE/Western blotting for the indicated proteins. Detection of β-actin served as loading control. (B-D) NSCLC (B and C) or SCLC (D) cells were treated with increasing concentrations of dasatinib (B and D), PP2 (C and D) or SKI-1 (D) and cell growth was monitored by crystal violet staining (B and C) or WST1 assay (D). Graphs represent means ± SEM from three independent experiments performed in triplicate and normalised to control. (D) Statistical analysis was performed using ANOVA (*p < 0.05, **p < 0.01, ***p < 0.005).